HBOT Conversations:
Join us for interviews with researchers, practitioners, industry experts, and patients to share their stories, successes, and expertise relative to hyperbaric oxygen therapy
Subscribe. Join the discussion. Share the hope.
Listen to or Watch the HBOT Conversations Podcast
Listen to the HBOT Converstations podcast by downloading it from your favorite podcasting platform or scroll down and watch an episode here on the HBOT News website:
Watch the HBOT Conversations Podcast
Subscribe Now, It’s Free !
Recent HBOT News
Experimental observation of hyperbaric oxygen combined with radioactive seed implantation in the treatment of nude mice bearing esophageal squamous cell carcinoma.
Abstract: Objective: To investigate the effect and mechanism of hyperbaric oxygen combined with radioactive seed implantation in the treatment of esophageal squamous cell carcinoma. Methods: Subcutaneous tumor model of esophageal squamous cell carcinoma using TE-8...
[Hyperbaric oxygen therapy in the treatment of diabetic foot: experience in the management of 80 cases at a department of internal medicine].
Abstract: Jira, El Omri, Sekkach, Mekouar, Amezyane (2018). [Hyperbaric oxygen therapy in the treatment of diabetic foot: experience in the management of 80 cases at a department of internal medicine]. The Pan African medical journal,...
Clinical Trial – Accelerated Hypofractionated Intensity – Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma.
This is a pilot study of radiotherapy using Hypofractionated image – guided helical
tomotherapy after hyperbaric oxygen HBO therapy for treatment of recurrent malignant
High-grade gliomas. HBO therapy will be perform in conjunction with each RT session.
The treatment scheme is:
Hyperbaric oxygenation therapy (the maximum period of time from completion of decompression
to RT is 60 min) followed by tomotherapy (3-5 consecutive sessions- one fraction per day , 5
Gy / die ).
The trial will enroll 24 patients in 24 months with a follow-up period of 1 year.